Zur Rose Group AG successfully completed a capital increase from authorized capital and set the placement price of CHF 287 per new share. A total of 740,823 new shares were sold in an accelerated bookbuilding to institutional investors. Accordingly, Zur Rose raised gross proceeds of CHF 213 million. Jefferies and Bank of America acted as Joint Global Coordinators and Joint Bookrunners.
Zur Rose Group intends to use the gross proceeds from the capital increase (i) to fund an accelerated roll out of its e-prescription solutions (eRx) and European growth initiatives to broaden its customer base through organic expansion as well as potential acquisitions, (ii) to invest in platform and ecosystem partnerships and (iii) to fund the acquisition of TeleClinic, as well as (iv) for general corporate purposes.
The new shares are admitted to trading on the International Reporting Standard segment of SIX Swiss Exchange as of July 21, 2020.
Baker McKenzie advised Zur Rose Group AG on all legal aspects of the accelerated bookbuilding and capital increase. The Baker McKenzie team consisted of Dr. Matthias Courvoisier (Partner), Dr. Yves Mauchle (Senior Associate) and Jan Lusti (Trainee) as well as U.S.-qualified lawyers Adam Farlow (Partner) and Charles Farnsworth (Of Counsel).